News

Segment‑level outlooks: the Healthcare unit is expected to achieve an 8.1 % YoY revenue gain, driven by its continued strong growth trend. The Applied Sterilization Technologies (AST) segment is projected to grow organically and benefit from rising bioprocessing demand. Life Sciences is anticipated to uphold the robust expansion seen in consumables...

Full article

Despite robust forward metrics, risks remain. Execution complexity and customer concentration could delay progress, while the firm’s zero‑carbon claims are disputed. Aggressive leverage threatens dilution, and the valuation already assumes a flawless rollout, leaving little room for cost overruns.

Full article

Strategic partnerships reinforce the company’s scale plans. TeraWulf signed an $8.7 billion, 10‑year lease with Fluidstack, and the two firms will jointly develop a 168‑MW HPC facility in Texas. These commitments position the firm to grow from 22.5 MW of energized HPC capacity to nearly 600 MW in the 2026‑2027 window, meeting the projected demand f...

Full article

The company’s pivot from pure‑play bitcoin mining to high‑performance computing (HPC) and AI data‑centre infrastructure has brought it to a key inflection point. As of Q3 2025, TeraWulf saw 84 % year‑over‑year growth and posted positive adjusted EBITDA, with a forward P/E of 29.76. Its forward revenue is anchored by $6.7 billion of contracted HPC b...

Full article

TeraWulf Inc. (NASDAQ: WULF) closed its Tuesday session at $15.31, up 11.02% from a $13.79 close on January 26. The rally was driven by heightened sector optimism after Nvidia’s $2 billion investment in CoreWeave, underscoring confidence in AI infrastructure.

Full article

The company carries a Zacks Rank of #4 (Sell), reflecting a perception of underperformance relative to the broader market, although recent earnings surprises and capital‑allocation plans provide a counter‑signal. The stock has gained approximately 8.4 % in value since the start of the year, outpacing the S&P 500’s 1.9 % gain.

Full article

Scotts is also finalising the divestiture of its cannabis‑focused business, which posted a discontinued‑operations loss of $77.2 million in the quarter. By shedding the unit, the company intends to sharpen its focus on core consumer and agriculture segments.

Full article

Shareholder value initiatives have intensified. A new $500 million share‑repurchase program has been launched, with the objective of reducing the share count to roughly 40 million and positioning the stock well above $100 if long‑term targets are achieved. Management projects shareholder returns in excess of 50 % from this program and the broader s...

Full article

Despite the loss, the firm maintained its full‑year guidance. For fiscal 2026, management reiterated the target of adjusted earnings per share of $4.15‑$4.35, low‑single‑digit growth in U.S. consumer net sales, a non‑GAAP adjusted gross margin rate of at least 32 %, mid‑single‑digit non‑GAAP adjusted EBITDA growth, and free cash flow of $275 millio...

Full article

The company recorded a net loss of $125 million, or $2.16 per share. After excluding one‑time items, the adjusted loss stood at $0.77 per share, narrower than the consensus expectation of a $1.04 per share loss, yielding an earnings surprise of +25.68 %. This marks the third time in four quarters that Scotts missed a loss estimate but exceeded it.

Full article